Effectiveness Or Bust: Without Benefit, No Case For Keeping Makena On The Market, CDER Says

Makena hearing and driving risks
FDA's Christine Nguyen aimed to center efficacy in the discussion by noting that everything involves risks, and people wouldn't drive cars unless it got them somewhere. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Review Pathways

More from Pathways & Standards